Treatment of advanced cutaneous squamous cell carcinoma: a Mohs surgery and dermatologic oncology perspective

Locally advanced or metastatic cutaneous squamous cell carcinoma no longer amenable to surgical resection or primary radiation therapy requires an alternative approach to treatment. Until 2018, management consisted of limited systemic chemotherapies, which carried marginal clinical benefit. The intr...

Full description

Saved in:
Bibliographic Details
Published in:Future oncology (London, England) England), 2021-12, Vol.17 (35), p.4971-4982
Main Authors: Wilmas, Kelly M, Nguyen, Quoc-Bao, Patel, Jigar, Silapunt, Sirunya, Migden, Michael R
Format: Article
Language:English
Subjects:
advanced cutaneous squamous cell carcinoma
Biomarkers, Tumor
Carcinoma, Squamous Cell - diagnosis
Carcinoma, Squamous Cell - etiology
Carcinoma, Squamous Cell - therapy
cemiplimab
Clinical Decision-Making
Clinical Trials as Topic
Combined Modality Therapy
Dermatology - methods
Dermatology - standards
Disease Management
Humans
immunotherapy
locally advanced cutaneous squamous cell carcinoma
Medical Oncology - methods
Medical Oncology - standards
metastatic cutaneous squamous cell carcinoma
Mohs Surgery - adverse effects
Mohs Surgery - methods
Mohs Surgery - standards
Molecular Targeted Therapy
Neoplasm Metastasis
Neoplasm Staging
oncholytic immunotherapy
pembrolizumab
radiation therapy
targeted therapy
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Locally advanced or metastatic cutaneous squamous cell carcinoma no longer amenable to surgical resection or primary radiation therapy requires an alternative approach to treatment. Until 2018, management consisted of limited systemic chemotherapies, which carried marginal clinical benefit. The introduction of immunotherapy with anti-PD-1 antibodies resulted in alternative treatment options for advanced cutaneous squamous cell carcinoma with substantial antitumor activity, durable response and acceptable safety profile. The field of immunotherapeutics continues to expand with adjuvant, neoadjuvant and intralesional studies currently in progress. Herein, the authors discuss their approach for the treatment of advanced cutaneous squamous cell carcinoma from the perspective of a Mohs surgeon and a dermatologic oncologist.
ISSN:1479-6694
1744-8301
DOI:10.2217/fon-2021-0901